| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1377561 | Bioorganic & Medicinal Chemistry Letters | 2007 | 4 Pages |
Abstract
Pyrrolopyrimidine nucleoside 1 was designed and synthesized as a potential mutagen for HCV. An in vitro HCV NS5B enzymatic assay indicated that pyrrolopyrimidine triphosphate acts as a CTP analog rather than a UTP analog. The SATE-prodrug of pyrrolopyrimidine monophosphate showed a weak inhibitory activity in an HCV replicon system (EC50 = 60 μM) and did not exhibit cytotoxicity (CC50 > 100 μM). Investigation of phosphorylation events using nucleoside kinases and LC–MS analysis revealed that the second phosphorylation step, from monophosphate ester to diphosphate ester, is unfavorable.
Graphical abstractPotential mutagen for HCV that could serve as a cytidine or a uridine.Figure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Yung-Hyo Koh, Jae Hoon Shim, Jean-Luc Girardet, Zhi Hong,